256 related articles for article (PubMed ID: 33526915)
1. Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1.
Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ; Lee S
Bone Marrow Transplant; 2021 Jul; 56(7):1603-1613. PubMed ID: 33526915
[TBL] [Abstract][Full Text] [Related]
2. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
3. Higher Cryopreserved CD34
Kato S; Konuma T; Monna-Oiwa M; Isobe M; Takahashi S; Nannya Y
Transplant Cell Ther; 2022 Nov; 28(11):779.e1-779.e9. PubMed ID: 35995391
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.
Song JS; Seo JJ; Moon HN; Ghim T; Im HJ
J Korean Med Sci; 2006 Oct; 21(5):897-903. PubMed ID: 17043426
[TBL] [Abstract][Full Text] [Related]
5. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
Lewis C; Kim HT; Roeker LE; Cutler C; Koreth J; Nikiforow S; Armand P; Gootpu M; Romee R; Glotzbecker B; Nageshwar P; Antin JH; Alyea EP; Richardson P; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2020 Mar; 26(3):529-539. PubMed ID: 31678537
[TBL] [Abstract][Full Text] [Related]
6. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation.
Cheuk DK; Chiang AK; Ha SY; Chan GC
Cochrane Database Syst Rev; 2015 May; 2015(5):CD009311. PubMed ID: 26017019
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study.
Putta S; Young BA; Levine JE; Reshef R; Nakamura R; Strouse C; Perales MA; Howard A; Pine P; Shi J; Zhang P; Ho VT; Saber W
Transplant Cell Ther; 2023 Mar; 29(3):166.e1-166.e10. PubMed ID: 36574581
[TBL] [Abstract][Full Text] [Related]
8. Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin.
Stutz L; Halter JP; Heim D; Passweg JR; Medinger M
Bone Marrow Transplant; 2022 Mar; 57(3):391-398. PubMed ID: 34980902
[TBL] [Abstract][Full Text] [Related]
9. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group.
Faraci M; Bertaina A; Luksch R; Calore E; Lanino E; Saglio F; Prete A; Menconi M; De Simone G; Tintori V; Cesaro S; Santarone S; Orofino MG; Locatelli F; Zecca M
Biol Blood Marrow Transplant; 2019 Feb; 25(2):313-320. PubMed ID: 30266674
[TBL] [Abstract][Full Text] [Related]
10. The Prophylaxis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome With Defibrotide After Hematopoietic Stem Cell Transplantation in Children: Single Center Experience.
Karagun BS; Akbas T; Erbey F; Sasmaz İ; Antmen B
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e35-e39. PubMed ID: 34966102
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of defibrotide in the prevention of hepatic venooclusive disease among adult patients receiving allogeneic hematopoietic cell transplantation: A retrospective single center experience.
Kayikci O; Akpinar S; Tekgunduz E
Transfus Apher Sci; 2022 Feb; 61(1):103369. PubMed ID: 35120824
[TBL] [Abstract][Full Text] [Related]
12. Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study.
Ruutu T; Peczynski C; Houhou M; Polge E; Mohty M; Kröger N; Moiseev I; Penack O; Salooja N; Schoemans H; Duarte RF; Schroeder T; Passweg J; Wulf GG; Ganser A; Sica S; Arat M; Salmenniemi U; Broers AEC; Bourhis JH; Rambaldi A; Maertens J; Halaburda K; Zuckerman T; Labussière-Wallet H; Basak G; Koenecke C; Perić Z
Bone Marrow Transplant; 2023 Nov; 58(11):1209-1214. PubMed ID: 37573397
[TBL] [Abstract][Full Text] [Related]
13. Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome.
Lai X; Liu L; Zhang Z; Shi L; Yang G; Wu M; Huang R; Liu R; Lai Y; Li Q
Bone Marrow Transplant; 2021 Jul; 56(7):1635-1641. PubMed ID: 33608657
[TBL] [Abstract][Full Text] [Related]
14. Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide.
Gómez-Centurión I; Bailén R; Oarbeascoa G; Muñoz C; Luque AÁ; Boyra ME; Calleja E; Rincón D; Dorado N; Barzallo P; Anguita J; Díez-Martín JL; Kwon M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2089-2097. PubMed ID: 32791193
[TBL] [Abstract][Full Text] [Related]
15. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
[TBL] [Abstract][Full Text] [Related]
16. Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment.
Dalle JH; Giralt SA
Biol Blood Marrow Transplant; 2016 Mar; 22(3):400-9. PubMed ID: 26431626
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients.
Corbacioglu S; Kernan NA; Pagliuca A; Ryan RJ; Tappe W; Richardson PG
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1342-1349. PubMed ID: 32200121
[TBL] [Abstract][Full Text] [Related]
18. Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD).
Yoon JH; Yoo KH; Sung KW; Jung CW; Kim JS; Hahn SM; Kang HJ; Lee JH; Im HJ; Ahn JS; Kook H; Cho B; Lee JW
Bone Marrow Transplant; 2019 Aug; 54(8):1361-1368. PubMed ID: 30809031
[TBL] [Abstract][Full Text] [Related]
19. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Corbacioglu S; Topaloglu O; Aggarwal S
Clin Drug Investig; 2022 Jun; 42(6):465-476. PubMed ID: 35594010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
